Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Review Of Reviews: Drug Review Profiles 2014

Dec 17 2014

Related Content

What’s In A Name? Janssen’s Loss Of <em>Sovriad</em> Was Gilead’s Gain With <em>Sovaldi</em>

May 22 2014

FDA Review Of GE’s <em>Vizamyl</em> Shows Caution In The Face Of Alzheimer’s Disease Unknowns

Feb 19 2014

Low Survival To Adulthood Key To <em>Vimizim</em> Pediatric Priority Voucher

Nov 19 2014

FDA Awaits Data On Clinical Significance Of <em>Vimizim</em> Neutralizing Antibodies

Nov 19 2014

In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin

Nov 19 2014

FDA Quietly Consults Patients To Understand Six-Minute Walk Significance

Nov 19 2014

<em>Zykadia</em> Expedited Timeline Challenged By Late-Breaking GMP Concern

Jun 18 2014

Biogen Idec Suggests PML Risk Manageable For <em>Tecfidera</em>, After Reporting First Case

Oct 24 2014

Unintended Consequences Of REMS Weighed On <em>Entyvio</em> Review Team

Oct 24 2014

Legacy Cost: Takeda’s <em>Entyvio</em> Development Shaped By <em>Tysabri</em> Fallout

Oct 24 2014

<em>Sovaldi</em> NDA Review Marred By Manufacturing Compliance Issues

Apr 22 2014

FDA Changed Course On <em>Zontivity </em>Because Of Skepticism Of Subgroups At High Levels

Jul 30 2014

How <em>Sovaldi</em> Won A Broad Label: Emerging Data Swayed Reluctant FDA

Mar 19 2014

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window